Does reducing spasticity translate into functional benefit? An exploratory meta-analysis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 11, 2004, Pages 1547-1551

  Francis, H P ^a   Wade, D T ^b   Turner Stokes, L ^c   Kingswell, R S ^a   Dott, C S ^a   Coxon, E A ^a  

^a IPSEN   (France)

^b OXFORD CENTRE FOR ENABLEMENT   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ARM MOVEMENT; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DRUG DOSE REGIMEN; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; META ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; PARAMETER; PRIORITY JOURNAL; SCORING SYSTEM; SPASTICITY; STROKE; SYSTEMATIC REVIEW;

ACTIVITIES OF DAILY LIVING; AGED; ARM; BOTULINUM TOXIN TYPE A; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MOTOR ACTIVITY; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 7244243788     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.025551     Document Type: Article

References (22)

1. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6.
2. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-65.
3. Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-21.
4. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
5. Rodriquez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000;79:44-7.
6. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10.
7. Yablon SA, Agana BT, Ivanhoe CB, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labelled trial. Neurology 1996;47:939-44.
8. Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
9. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
10. Bhakta BB, Cozens JA, Bamford JM, et al. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5.
11. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001;14:771-6.
12. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990;28:512-5.
13. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-9.
14. Smith SJ, Ellis E, White S, et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
15. Ada L, Canning C, Dwyer T. Effect of muscle length on strength and dexterity after stroke. Clin Rehabil 2000;14:55-61.
16. Canning CG, Ada L, O'Dwyer N. Slowness to develop force contributes to weakness after stroke. Arch Phys Med Rehabil 1999;80:66-70.
17. Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000;79:377-84.
18. Collin C, Wade DT, Davis S, et al. The Barthel ADL Index; reliability study. Int Disabil Stud 1988;10:61-3.
19. Ottenbacher KJ, Cusick A. Goal attainment scaling as a method of clinical service evaluation. Am J Occup Ther 1990;44:519-25.
20. Richardson D. Evaluation of interventions in the management of spasticity: treatment goals and out-come measures. In: Sheean G, ed. Spasticity rehabilitation. London: Churchill Communications Europe Ltd, 1998:57-69.
21. Brin M. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Muscle Nerve 1997;6:S208-20.
22. World Health Organisation. The International Classification of Functioning, Disability and Health (ICF). Geneva, Switzerland: WHO, 2002.